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Abstract
Background: The MYC oncogene contributes to induction and growth of many cancers but the full spectrum of the MYC
transcriptional response remains unclear.
Methodology/Principal Findings: Using microarrays, we conducted a detailed kinetic study of genes that respond to MYCN
or MYCNDMBII induction in primary human fibroblasts. In parallel, we determined the response to steady state
overexpression of MYCN and MYCNDMBII in the same cell type. An overlapping set of 398 genes from the two protocols
was designated a ‘Core MYC Signature’ and used for further analysis. Comparison of the Core MYC Signature to a published
study of the genes induced by serum stimulation revealed that only 7.4% of the Core MYC Signature genes are in the Core
Serum Response and display similar expression changes to both MYC and serum. Furthermore, more than 50% of the Core
MYC Signature genes were not influenced by serum stimulation. In contrast, comparison to a panel of breast cancers
revealed a strong concordance in gene expression between the Core MYC Signature and the basal-like breast tumor
subtype, which is a subtype with poor prognosis. This concordance was supported by the higher average level of MYC
expression in the same tumor samples.
Conclusions/Significance: The Core MYC Signature has clinical relevance as this profile can be used to deduce an
underlying genetic program that is likely to contribute to a clinical phenotype. Therefore, the presence of the Core MYC
Signature may predict clinical responsiveness to therapeutics that are designed to disrupt MYC-mediated phenotypes.
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Introduction
The MYC proto-oncogene is an essential gene whose function is
required for normal mouse and fly development [1–3]. MYC is a
transcription factor that can both positively and negatively
regulate target gene expression (review [4]). Enormous strides
have been made in understanding the biochemical properties of
the MYC protein. Several nuclear cofactors such as TRRAP,
RUVBL1/Tip49, p300 and SKP2 have been shown to be
required for MYC induced transformation or transactivation [5–
9]. A large list of MYC target genes forms the core of a publicly
available MYC database [10]. Similarly, exhaustive studies have
recognized MYC’s ability to increase cellular proliferation,
transformation, apoptosis, and genetic instability, as well as to
inhibit cellular differentiation (reviewed in references [11–13]).
Despite these advances, the extraordinarily complex cellular
responses to MYC expression has made it difficult to decipher
the target genes that mediate these biological activities.
When translocated, amplified or misregulated, MYC can
function as a potent oncogene, and it is estimated that 20% of all
human cancers harbor an oncogenic allele of MYC (review [14]).
MYC deregulation has been directly implicated in many specific
types of cancer, including breast cancer. An early example of
aberrant MYC expression in breast tumor tissue described gene
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amplification in 32% of 121 breast tumors [15]. A comprehensive
review finds a consistent link between breast cancer and MYC
amplification or overexpression. These and other data linking MYC
deregulation with malignant transformation unequivocally reveal
MYC’s oncogenic potency, however the underlying transcriptional
mechanisms driving transformation remain unresolved.
MYC overexpressing cells exhibit reduced dependence on
serum for rapid proliferation and survival in culture [16,17]. It is
commonly believed that MYC enables cells to develop such
independence by directly or indirectly inducing or repressing those
genes that are normally regulated by serum stimulation. However,
there has never been a systematic analysis of this question. In vivo,
most cells experience serum stimulation normally only in the
context of local injury. The gene expression program in fibroblasts
in response to serum exhibits many features of the wound healing
response [18]. Motivated by the observation that wound healing
and tumor growth share many common physiological character-
istics (review, [19]), Chang and colleagues showed that the
expression of the serum response in cancer cells is a predicator
of cancer patient survival and metastasis [20]. More recently, they
propose a model in which the wound signature in breast cancer is
induced by the coordinate amplification of MYC and CSN5, a
component of a ubiquitin ligase complex [21].
New technologies are beginning to permit a better appreciation of
the complexity of the cellular response to MYC. Numerous high-
throughput studies queryingMYC regulated genes have recently been
published [22–32]. While many studies have focused on the discovery
of MYC target genes, few have examined the complete cellular
transcriptional changes induced by MYC. Interestingly, different
studies identify very different MYC responsive genes. Many
experimental variables like cell type, MYC protein levels, length of
time of aberrant MYC expression, etc. are likely to account for the
study-to-study discrepancies. In this study, we have attempted to
define a core MYC-responsive gene expression signature that is less
subject to many of the common experimental variables. We identified
a gene expression signature common to two cell culture models of
MYC overexpression and compare this profile to the gene expression
data from the serum response and from primary human breast
tumors. This approach allowed us to isolate the transcriptional
response to MYC in a controlled system and to then show that the
core MYC signature is present in a gene expression data set of breast
cancer samples, which identifies the basal subtype of breast cancer and
may indicate one of the genetic determinants of this group.
Materials and Methods
Cell Culture, Transfection and Retroviral Infection
MYCN-ERTM was created as a fusion between mouse MYCN
C-terminus and a portion of the estrogen receptor [33]. Stably
expressing oligoclonal cultures of primary human foreskin
fibroblasts were created using the LPCX vector. The constitutive
MYCN expression used a Flag-tagged mouse MYCN cDNA in the
LXSH retroviral vector. MYCNDMBII has been previously
described [34]. Primary human foreskin fibroblasts (BJ, ATCC
product #CRL-2522) and retroviral producer PhoeNX cells
(ATCC product #SD 3443) were cultured in DMEM supple-
mented with 10% fetal bovine serum. Retroviral infection of BJ
cells was performed using PhoeNX cells. To obtain a transduced
population, retrovirus infected cells were selected for resistance to
puromycin (0.8 mg/ml) or hygromycin (150 mg/ml) for 7 days.
Western blotting
Protein lysates were resolved by standard SDS-PAGE methods.
Proteins were transferred to PVDF and membranes were then
blocked for 109 to O/N in TBS (+0.1% Tween 20 and 1% skim
milk). Anti-FLAG western blots were probed with diluted (1:5000)
FLAG antibody (M2, Sigma) in blocking solution. Blots were
washed 3 times with TBS (+0.1% Tween 20). Diluted (1:10,000)
secondary antibody (HRP conjugated goat anti-mouse) was used
to detect primary FLAG antibody. Enhanced chemoluminescence
reagents (Amersham Biosciences) were used to detect HRP after
exposure to Kodak XAR film.
RNA preparation, labeling, and microarray hybridization
Total RNA was prepared from cells at times and conditions
indicated in text using the TRIzol reagent (GIBCO-BRL)
according to the manufacturer’s protocol. Reference RNAs were
made from rapidly dividing untransduced BJ cells. The Agilent
low input fluorescent linear amplification kit was used to generate
labeled cRNA for time course experiments from 0.5 mg of total
input RNA. Cy3-CTP and Cy-5 CTP were obtained from Perkin
Elmer/NEN Life Sciences. The Agilent fluorescent direct label kit
was used to generate labeled cDNA for steady state experiments
from 10 mg of total input RNA. A total RNA reference sample was
prepared from logarithmically growing normal primary BJ
fibroblasts. Reference RNAs were prepared separately for the
time course experiments and the steady state experiments.
Experimental samples labeled with Cy5 and reference samples
labeled with Cy3 were competitively hybridized to Agilent human
1A version 2, 22,000 element arrays in both the time course and
steady state studies. The exceptions were the five vector control
arrays in the time course study, which were hybridized to Agilent
human 1A version 1 arrays.
Hybridizations and washes were performed according to the
manufacturer’s protocol. Washed arrays were scanned using the
Axon Instruments GenePix 4000B microarray scanner and
intensities collected by using GenePix5.0 software. All reported
microarray data are MIAME compliant and are stored in the
UNC Microarray Database and the Gene Expression Omnibus
(GEO). The data can be accessed at https://genome.unc.edu/ or
at GEO under accession number GSE15523.
Microarray data analysis
Elements on the array flagged as ‘‘spot not found’’ or ‘‘spot
bad’’ were removed from data and not considered further. The
background subtracted LOWESS (for time course data) or global
linearly (steady state experiment) normalized data were filter for
spots with intensity at least 20% above background. In each time
course series (LCPX, MYCN-ER, or MYCN(DMBII)-ER), we
required the data for at least two of the three zero time points (for
a given probe) to pass the above criteria or the gene was removed
from further consideration. Similarly for the steady state
experiments, we required the data for both vector arrays for a
given probe to meet the above criteria or the gene was discarded.
Subsequently, only those probes that met the above criteria for at
least 80% of the 25 arrays in the time course experiment or of the
6 arrays in the steady state experiment were retained.
For a given probe in a time course series, the average expression
value across the three zeros was subtracted from every expression
value in that series. A similar zeroing was performed on the steady
state data except the vector expression values served as the zeroes.
In the time course data, genes that showed at least a 1.7 fold
change from the time zero point, in at least two arrays were
selected for further analysis. The probes (1631 probes) that pass
these filters for the time course experiment were considered
MYCN-ER responsive. SAM (Significance Analysis of Micro-
arrays, version 1.21) was used to perform a two-class, unpaired
analysis of the steady state data with the wild type MYCN arrays
MYC Gene Expression Signature
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in one class and the vector and mutant MYC arrays in another
[35]. The resulting probes (1608 probes) from this analysis were
considered MYCN responsive. Hierarchical clustering analyses
were performed with Cluster 3.0 [36].
The Core MYC signature centroid was calculated in three steps.
First, the average expression values for the Core MYC signature
genes across the last three time points (24, 36, and 48 hrs) in the
time course experiment were determined. Second, the average
expression values for the Core MYC Signature genes across the
duplicate MYCN arrays were determined. Finally, the average of
these two averages resulted in the Core MYC Signature centroid.
Therefore, the MYCN-ER induction and MYCN overexpression
studies equally contribute to defining the Core MYC signature
centroid.
When different expression profiling datasets were linked
together, publicly available datasets were first filtered, normalized
and centered as in the original study. Then, platform-specific clone
identifiers were converted (using Source and other utilities) to
UNIGENE cluster identifiers (unigene build 219, June 2009). Data
from multiple spots mapping to the same UNIGENE cluster ID
were averaged across the multiple spots. The data were then linked
by unique UNIGENE cluster IDs.
For all data presented as Java Treeview images, the contrast
setting was set to ‘‘2’’.
Classification of breast tissue samples from the Hu et al. and the
NKI295 datasets was based on the SSP/Spearman classification
system described in Hu et al. [37].
Immunohistochemistry
Paraffin-embedded breast tumors were cut into 5 mm sections.
Tissue sections were deparaffined with xylene, dehydrated with
ethanol and endogenous peroxidase activity was blocked with a
3% hydrogen peroxide solution. The slides were incubated with
10 mM citrate buffer (pH 6.0) and microwaved for 20 min for
antigen retrieval. The slides were then blocked with goat serum
and incubated with cMYC antibody for 30 min (Santa Cruz sc-40,
1:50 dilution), and then incubated with biotin conjugated goat
anti-mouse IgG (Vector Laboratories, CA, USA). Proteins were
visualized with streptavidin-conjugated HRP (Vector Laborato-
ries, CA, USA). The slides were counterstained with 50%
hematoxylin and examined by light microscopy on a Zeiss
microscope at6100 magnification.
Results
Experimental design
The pathology that results from MYC overexpression is the
consequence of altered expression of both direct and indirect target
genes. Hence, we designed our experiments to capture the complete
cellular transcriptional response to MYC overexpression rather than
try to limit our study to direct MYC target genes. Experiments to
identify MYC responsive genes were performed with human primary
foreskin fibroblasts harboring inducible or constitutive MYC
constructs. We chose to examine MYCN as a model member of
the MYC family of proteins. MYCN is a MYC family member that
acts similarly to MYC in most experimental systems [34,38] and in
gene response profiles (Cowling and Cole, manuscript in prepara-
tion). In addition to wildtype MYCN, we studied a mutant MYCN
with a deletion within MYC homology box II (MBII), a conserved
region among MYC family members shown to be essential for many
of MYC functions such as the regulation of some target genes,
transformation, proliferation, and apoptosis [34,39–41].
We created both inducible and stable expression vectors for
MYCN. MYCN-ERTM was created as a fusion protein between a
full length mouse MYCN cDNA and a portion of the estrogen
receptor [33]. We also used a constitutive MYCN vector for stable,
increased expression [34]. The exogenous inducible and constitu-
tive constructs were introduced into primary human foreskin
fibroblast cells by retroviral transduction, and expression from the
exogenous transgenes was confirmed by western blot (Supplemen-
tal Figure S1). Genome-wide gene expression was then analyzed
using oligonucleotide microarrays.
Overview of MYC induced Expression Profiles
For MYCN-ERTM, cells were expanded after viral transduction
and treated with 4- hydroxytamoxifen (4-OHT). Total RNA was
harvested in a time course. Untreated zero time points from three
biological replicates of the lines (vector, MYCN-ERTM,
MYCNDMBII-ERTM) were collected. Single vector control
samples were collected 8 and 48 hr following induction with 4-
OHT. Single samples of MYCN-ERTM and MYCNDMBII-
ERTM were collected 2, 4, 8, 12, 24, and 48 hr following
induction. Microarray analysis was performed on collected
samples. Genes that showed at least a 1.7 fold change from the
time zero point in at least two arrays were selected for further
analysis. Data from 1,631 probes (representing 1,449 unique
UNIGENE clusters (Build 219) that pass these filters for the time
course experiment were considered MYCN-ER responsive
(Supplemental Table S1). After filtering, the genes were organized
by one-dimensional hierarchical clustering (Figure 1A). To
confirm array results, eight randomly selected genes among the
MYCN responsive genes were examined by RT-PCR. Transcripts
for all eight genes showed similar patterns by both RT-PCR and
microarray analyses (data not shown).
Comparison of the gene expression profiles between MYCN-
ERTM and MYCNDMBII-ERTM provides insight into the
transcriptional defect in the latter mutant. MYCNDMBII-ERTM
is severely blunted, but not completely defective, in the number
and magnitude of both gene activation and repression (Figure 1A).
A similar conclusion was previously reached from the steady state
data[42]. The defect in activation and repression was roughly
equivalent. The genes induced or repressed by MYCNDMBII-
ERTM mutant were also generally delayed in response compared
to wt. A subset of genes are still induced and repressed by the
MYCNDMBII-ERTM mutant but further analysis will be required
to determine if these promoters have any unique features.
For comparison to the time course data, the same MYCN and
MYCNDMBII proteins were stably overexpressed in BJ fibro-
blasts, an experimental design that more closely approximates the
situation in tumors that have high MYC expression. Cells were
virally transduced with the constitutive MYCN expression
constructs, stably expressing cells were selected, and total cellular
RNA was harvested. Technical duplicates for vector, MYCN, and
MYCNDMBII cells were assayed for differentially expressed genes
using the same human oligonucleotide microarrays used for the
time course. Expression from the exogenous transgenes was
confirmed by western blot [42]. These data have been previously
presented in the context of another study [42], but will be
discussed here in comparison to the time course data and with
different statistical tools.
We used SAM (Significance Analysis of Microarrays, version
1.21) to perform a two-class, unpaired analysis with the wild type
MYCN arrays in one class and the vector and mutant MYCN
arrays in another [35]. SAM analysis was used to focus attention
on genes induced specifically by wildtype but not mutant MYCN.
SAM analysis identified 1608 differentially expressed probes with a
median false discovery rate of 0.42%. These 1,608 probes map to
1,407 unique UNIGENE clusters (Build 219) (Supplemental Table
MYC Gene Expression Signature
PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6693
S1). The identified steady state MYC responsive probes were
clustered hierarchically using Cluster 3.0 (Figure 1B).
Comparison to the ‘‘MYC Target Gene Database’’
Comparison of our study to previous studies that identified MYC
responsive genes underscores both the magnitude of the MYC
response as well as the differences inherent to the experimental
approaches. To be as inclusive as possible for comparisons, we
considered the MYC Target Gene database (http://www.myccan-
cergene.org/) as a repository of previously described MYC
responsive genes [10]. The MYC Target Gene database includes
MYC responsive genes identified in independent studies by SAGE,
DNA microarray, subtractive hybridization, ChIP, northern/
western blot or RT-PCR. To compare the MYCN-ER responsive
genes and the steady state MYCN responsive genes with a current
compilation of MYC targets in the MYCTarget Gene database, we
mapped MYCN responsive genes identified here, and those found
in the MYC cancer database to UNIGENE cluster IDs. The total
number of target genes from the MYC database is the number of
genes in the database that map to a unique UNIGENE ID
(UNIGENE Build 219) and that were represented on the Agilent
microarrays (1,378 genes). Similarly, the number of MYCN-ER
responsive (1,449 genes) or MYCN responsive genes (1,407 genes) is
the number of responsive probes that map to unique UNIGENE
clusters (UNIGENE build 219). In Figure 2, we compare these data
in a Venn diagram. When individually compared to the MYCN
database, the MYCN-ER responsive genes overlap with only 255
genes out of 1,378 database genes and the steady state MYCN
responsive genes overlap with only 265 out of 1,378 database genes.
Surprisingly, only 101 genes are common to all three groups (all
genes in this analysis are provided in Supplemental Table S3). Thus,
our analysis reveals a very large set of previously unrecognized
MYC responsive genes. It is important to add that this lack of
overlap among MYC responsive genes is consistent with other
analyses of expression and computationally derived gene sets [31].
Definition of the Core MYC signature
The two different data sets from induced and steady state
MYCN overexpression suggest that the response to MYCN
overexpression can be quite variable, depending on the method
Figure 1. Microarray data of MYCN responsive genes. A) Probes from the MYCN-ER time course experiment after clustering. Probes were
selected as described in Methods and the expression data was subjected to hierarchical clustering. B) Probes from the MYCN steady state expression
studies after selection and hierarchical clustering. Complete lists of probes/genes are provided in Supplemental Table S1.
doi:10.1371/journal.pone.0006693.g001
MYC Gene Expression Signature
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and timing of delivery. We reasoned that the genes common to the
MYCN response in both experimental approaches would serve as
a conservative estimate of a core ‘MYC gene expression signature’.
Thus, we chose to focus on the genes responsive to MYCN
overexpression in both experimental designs. Here forward we
refer to this expression profile as the ‘Core MYC Signature’
(Figure 3).
The Core MYC Signature consists of 428 probes that map to
398 unique UNIGENE clusters (Build 219) (Figure 3, Supple-
mental Table S1). Of these genes, 354 (89%) have the same
direction of response in both studies (Figure 3). We assessed the
GO term annotations for the clusters of Core MYC signature
genes that display a common direction of response and found that
the induced genes and repressed genes have a very similar set of
overrepresented GO Terms to that found in the individual studies
described below (see below, Supplemental Table S2).
The different experimental designs dictated different methods of
categorizing genes as MYCN responsive. We were interested in
further examining the genes classified as responsive in one
experimental design, but not the other. To do this, we examined
the expression data of the probes in the non-overlapping areas of
the Venn diagram in Supplemental Figure S2. We noticed that a
substantial number of these non-overlapping genes were appar-
ently responsive in both studies. Further analysis shows that while
many of theses genes do respond in both studies, the response is
weak or noisy in one study thereby not passing the previously
decided criteria for MYCN responsiveness. Lowering the thresh-
olds for MYCN responsiveness leads to a larger group of
overlapping genes. One explanation for these differences could
be the kinetics of target gene response. MYCN-ER is activated
transiently for a few hours whereas the steady state cells took three
weeks of continuous culture to expand the polyclonal population.
Short term versus long-term response to high MYCN levels could
alter the magnitude and spectrum of the gene expression profiles.
MYCN responsive genes
Gene Ontology (GO) terms allow gene lists to be interrogated
for the overrepresentation of specific biological processes. Gene
Ontology TermFinder (version 0.61) is a statistical tool (with
multiple hypothesis testing correction) to measure the overrepre-
sentation of GO terms in clusters of similarly responding genes
[43]. The enrichment of GO terms among the clusters of MYCN
responsive genes provides an unbiased assessment of specific
biological processes that are nonrandomly represented in each
cluster. Analysis of GO term enrichment in clusters of genes that
are regulated by MYCN-ER, MYCN and also those in the Core
MYC Signature reveals many significantly overrepresented GO
Biological Process terms. For induced genes, there is a striking
overrepresentation of genes involved in translation, protein
biosynthesis, ribosome biogenesis and assembly, RNA processing,
and nucleotide metabolism (Table 1, Supplemental Table S2). In
the long-term model of MYCN overexpression, the GO terms cell
proliferation and DNA replication are also overrepresented (see
Supplemental Table S2 for p-values). These data are consistent
with several previous reports identifying similar links between
protein synthesis and MYC, strongly suggesting that MYCN
overexpression results in an increase in general protein synthe-
sis.[44,45]. Genes involved in ribosome biogenesis such as FBL
(Fibrillarin), NPM1 (Nucleophosmin 1), NOL5A (Nucleolar
protein 5A) and EBNA1BP2 (EBNA1 binding protein 2B) are
upregulated by MYC overexpression (Figure 2). Similarly, genes
that encode products more directly involved in protein synthesis
such as 60S ribosomal protein L32, 39S ribosomal protein L45,
40S ribosomal proteins S3 and S4 (Y isoform), 28S ribosomal
protein S9 and MetAP2 (Methionine aminopeptidase 2) are also
upregulated (Figure 2).
Enriched GO terms among the repressed genes revealed a
striking trend. Genes involved in development, signal transduction
and cell communication are repressed (Table 2 and Supplemental
Table S2). A common element in these biological processes is that
each involves the cell’s ability to recognize and communicate
external cues to the nucleus. Genes such as Rit1 (Ras-like GTP-
binding protein), STAT1 (Signal transducer and activator of
transcription 1), EDG2 (LPA receptor), ITGB1 (Fibronectin
receptor, Integrin beta 1), SOS-1 (Son of sevenless protein
homolog 1) are repressed and involved in these processes. Finally,
among the repressed genes, we found that there was an
overrepresentation of genes whose products are extracellular
(p,3.861028). (Supplemental Table S2).
Several attributes of the list of repressed genes are notable. First,
the number of repressed genes forms a significant portion of the
complete transcriptional response. In the MYCN-ER experiments,
approximately 48% of the response corresponds to repressed
genes. In the MYCN steady state experiments, approximately
41% of the MYC response is composed of repressed genes.
Second, a substantial fraction of the repression response initiated
by MYCN-ER activation occurred as rapidly as the earliest
induction response. Rapid repression will only be observed for
genes with rapid mRNA turnover, so repressed genes may be
underrepresented in the early points of a time course. For
example, PDGFR-alpha peptide (platelet derived growth factor
receptor, alpha peptide 1), DUSP1 (dual specific phosphatase 1)
and ARHE (Ras homolog gene family member E) show a
repression response after only two hours of MYCN-ER activation
(Figure 3). Third, as discussed above, GO term enrichment
Figure 2. Venn diagram of MYC responsive genes in different
studies. MYC responsive genes in our studies and those found in the
MYC cancer database were mapped to unique unigene cluster ID’s. The
total number of target genes from the MYC database is the number of
genes in the database that map to unique unigene cluster ID’s and that
had a probe on the Agilent arrays.
doi:10.1371/journal.pone.0006693.g002
MYC Gene Expression Signature
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analysis shows that many of the repressed genes appear to be
involved in communicating to other cells or in responding to
extracellular signals (Table 2 and Supplemental Table S2).
Analysis of MYC binding sites in Core MYC signature
genes
To gain insight into which of the Core MYC signature genes are
likely to be direct targets, we compared the gene set to two recently
Table 1. Representative subset of enriched GO terms among
induced MYC signature genes.
Enriched GO terms among induced
MYC signature genes
P-value
(Bonferroni-corrected)
RNA processing 0.00E+00
RNA metabolism 1.16E-09
ribosome biogenesis 4.96E-09
rRNA processing 4.56E-06
mRNA processing 1.53E-04
RNA splicing 1.16E-03
regulation of translation 7.21E-03
protein biosynthesis 7.51E-03
doi:10.1371/journal.pone.0006693.t001
Figure 3. The Core MYC gene expression signature. Expression data for probes that are identified as responsive to both MYC-ER activation and
steady state MYC overexpression are hierarchically clustered. The expression response of these probes is defined as the Core MYC signature. The
signature probes total 428 Agilent probes that can be mapped to 385 unique unigene clusters.
doi:10.1371/journal.pone.0006693.g003
Table 2. Representative subset of enriched GO terms among
repressed MYC signature genes.
Enriched GO terms among repressed
MYC signature genes
P-value (Bonferroni-
corrected)
development 1.54E-04
blood coagulation 1.81E-03
wound healing 2.36E-03
hemostasis 2.58E-03
signal transduction 2.76E-03
cell communication 4.12E-03
response to external stimulus 1.31E-02
doi:10.1371/journal.pone.0006693.t002
MYC Gene Expression Signature
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published studies that used chromatin immunoprecipitation to
define genome-wide MYC binding sites in embryonic stem (ES)
cells (see Supplemental Table S5 for full comparisons) [46,47]. Of
the total 398 MYC signature genes, 146, or 36.7%, have direct
binding sites mapped by Kim et al.(2008) or by Kidder et al.(2008)
Interestingly, of the Core MYC Signature genes that are induced
by MYCN-ER or by MYCN, 134/254 (52.8%) have direct
binding sites mapped by Kim et al.(2008) or by Kidder et al. In
stark contrast, of the Core MYC Signature genes that are
repressed by MYCN-ER or by MYCN, only 22/164 (13.4%) have
direct binding sites mapped by Kim et al.(2008) or by Kidder et al.
See Supplemental Table S6 for full enumeration of lists in Table 3.
These data are consistent with established mechanisms of MYC
activity - activated genes usually have MYC bound proximal to the
promoter whereas repressed genes rarely, if ever, have canonical
MYC binding sites [48]. Despite the sizeable fraction of MYCN/
MYCN-ER induced genes having evidence for direct MYC
binding, this analysis is a comparison of fibroblast expression data
to embryonic stem cell MYC binding data. Therefore, there is a
strong likelihood that genes that are regulated in the MYC
signature may indeed have MYC bound at their promoters, but
are simply not regulated and bound in ES cells.
Analysis of the Core MYC Signature in a serum response
dataset
The c-MYC gene was the first oncogene shown to be part of the
immediate early response to serum stimulation [16]. Therefore, it
was of interest to compare the response of fibroblasts to MYCN
overexpression with their response to serum. We utilized a publicly
available serum stimulation gene expression dataset of normal
human fibroblasts, and a list of genes determined to represent the
‘‘Core Serum Response’’ (CSR) [20]. A priori, we expected that
MYCN overexpression might induce a gene expression response
that was similar to the serum response. Specifically, we thought
that MYCN would induce genes that are called delayed early
response genes. Delayed early response genes are defined as those
that are dependent on the initial induction of a transcriptional
regulator or signaling pathway. This initial transcriptional
response subsequently induces a secondary set of genes that are
not induced by the primary signal. These expectations were met
for a fraction of the CSR genes that could be mapped to our array
platform (Figure 4A). A set of genes (80 out of 354; 23%) is
induced both by MYCN and by serum, and the kinetics of
induction in the CSR are consistent with these genes being
downstream of MYC. In the serum induced gene profiles, the c-
MYC gene itself is induced at 2–4 hr, similar to the response
described in numerous studies. However, in the MYCN-ER and
steady state overexpression profiles, the c-MYC gene itself scores
as repressed due to autoregulation. It is important to add that
although there is an overlap between the CSR and MYCN
induction, many of the CSR genes would not have passed the
threshold as MYC targets in either the kinetic or steady state
experiments. Not surprisingly, many CSR genes are not MYCN
responsive, implying that these genes are regulated by MYC
independent pathways or require some combinatorial signal.
A somewhat different pattern emerged when we analyzed the
Core MYC signature gene set for their response to serum
(Figure 4B). 298 genes of the Core MYC signature genes were
represented on the arrays of the serum response study. 30 of these
genes are found in the CSR. Of these 30 genes, 22 of the Core
MYC signature genes displayed a concordant response in the
CSR, i.e. were induced or repressed the same. The concordant 22
genes of the 298 Core MYC signature gene set represents a
statistically significant overlap (p-value,8.661025). These 22
genes (7.4%) were induced or repressed by serum with kinetics
consistent with them being MYC-dependent delayed early genes
(Supplemental Table S4). Interestingly, many of the concordant
genes consistently upregulated by both MYCN and serum are
involved in formation and maturation of ribosomes (FBL,
EBNA1BP2, NOL5A) [45,49,50]. In contrast, greater than 50%
of the Core MYC Signature genes were not induced or repressed
by serum at all (i.e. REPIN1, LARS, SARS2). Some genes induced
or repressed by MYC exhibited the opposite response to serum
(i.e. TFPI2, ITGA2, VEGFC, F3) (Figure 4B). Expanding the
analysis to the larger sets of genes responsive to MYCN-ER or
steady state MYCN does not appreciably change the percentage
overlap (data not shown). Thus, MYCN induces a large set of
genes that are not significantly induced by normal serum growth
factors. For a summary of the comparisons, see Supplemental
Table S4.
Systematic analysis of the Core MYC Signature in breast
tumors
We next assessed the expression of the Core MYC signature in
the pathophysiological settings of tumors. Since MYC is frequently
amplified and overexpressed in breast cancers, we extracted the
genes of the Core MYC signature from expression profiles of a set
of 146 breast tissue samples that were previously hybridized to the
same Agilent human oligonucleotide microarrays [37], and we
determined if the Core MYC signature is found in any of the
previously defined subtypes of breast tumors. We first used the
Core MYC signature gene list to cluster the breast tumor samples
hierarchically in two dimensions, which groups the tumors into
two main clusters (Figure 5). To examine the robustness of the
sample groupings, we used Significance of Clustering (SigClust)
[51]. We find the two major bifurcations in the dendrogram tree
are significant (p,0.001). The left (red) branch of the dendrogram
includes all of the basal-like tumors and only nine non-basal tumor
samples (seven are HER2+/ER2 tumors and two are luminal-
type tumors) (Figure 5A, Table 4). The right dendrogram branch
is not composed of one predominant subtype as was seen for the
left cluster, and contained a mix of Luminal, HER2+, and
Normal-like samples (Table 4). The distribution of tumor subtypes
in the two clusters suggests a statistically significant relationship
between the cluster grouping and subtype (using a chi-square
analysis) (Table 4).
The observation that the genes of the Core MYC signature can
drive the grouping of the basal tumors suggests that MYC itself
may be coordinately expressed with the signature in this subtype.
To explore relative differences in MYC RNA levels across the
tumors, we displayed the median centered data for MYC in a
Table 3. MYC-bound Core MYC signature genes.
Induced MYC Signature genes 254
That have a direct MYC binding site 134
Percentage 52.8%
Repressed MYC Signature genes 164
That have a direct MYC binding site 22
Percentage 13.4%
The regulated genes in this table include MYC Signature genes that are
regulated in the indicated fashion by either MYCN-ER or by MYCN. The genes
that are indicated as having direct MYC binding sites are those identified in the
Kim et al.(2008) or Kidder et al. study.
doi:10.1371/journal.pone.0006693.t003
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histogram below the tumor samples (Figure 5B). Among the tumor
samples, the basal tumors have the highest average MYC levels.
Furthermore, the general expression pattern (induced or repressed)
of Core MYC signature genes in the basal tumors most closely
parallels the response of these genes to ectopic MYCN expression
in primary fibroblasts. Interestingly, some of the normal breast
tissue samples that cluster on the right (blue) branch of the array
dendrogram have relatively high MYC expression but display an
expression profile that is clearly distinct from the samples in the left
cluster of mostly basal-like tumors.
Detecting the presence of the Core MYC signature
To quantify the relationship between the Core MYC signature
response and the expression profile of an individual tissue, we first
calculated a Core MYC signature centroid to which the
resemblance of each expression profile is calculated as a Pearson’s
correlation. A similar strategy was previously employed to calculate
the presence of the ‘‘wound signature’’ in tumor expression profiles
[52]. In our study, we use this correlation value as a means to
describe the presence of the Core MYC signature in a given sample.
However, it is difficult to decide a threshold correlation value above
which one would classify a sample as definitively displaying the Core
MYC signature. For comparison, the absolute value of a correlation
score describing the presence of the wound signature in a tumor
sample of greater than 0.15 had substantial predictive clinical
consequences [52]. The Pearson correlations between the MYC
centroid and breast tumor expression profiles are presented in
Figure 5C. The left and right clusters display average correlation
scores of 0.16, and 20.13, respectively. In the left cluster, most
tumors had a positive correlation score and some tumors had
correlation scores greater than 0.5.
To more objectively search for associations between the Core
MYC signature and tumor subtype, we created an ‘‘average
expression profile’’ for each patient across the Core MYC
signature genes by simply deriving an average expression value
across all Core MYC signature genes for each sample. Next, the
patients were put into rank expression order based upon this
average Core MYC signature expression value. The patients were
then put into either the ‘‘low’’ or ‘‘high’’ Core MYC signature
expression groups based upon a 50/50 split of the samples. Using
chi-squared analyses where the distinction of high vs. low is
compared to the classification of intrinsic subtype in the Hu et al.
set of 146 samples analyzed, a statistically significant relationship
between the Core MYC signature average expression and subtype
was observed (Table 5); the higher average expression was most
commonly seen in the basal-like tumors that frequently show 8q24
amplification [53], and the lower average expression was observed
more often in the good outcome Luminal A subtype. Similar
results were obtained when an identical analysis was performed on
the NKI295 sample set of van’t Veer et al., and van de Vijver et al.
[54,55] (Table 6). Lastly, using this Core MYC signature average
profile and the distinction of ‘‘high’’ vs. ‘‘low’’ expression, we
Figure 4. Serum stimulation vs. MYC overexpression. A. The expression profiling data for serum responsive study [20] and this study were
linked. The data corresponding to the (CSR) gene list were extracted from the linked dataset. The data for these genes were hierarchically clustered in
one dimension (genes). Upon serum stimulation, samples were harvested from 0 hrs to 36 hrs. B. The same procedure was performed starting with
the Core MYC signature gene list. The data for each of the Core MYC signature genes was extracted from the linked dataset and clustered in one
dimension.
doi:10.1371/journal.pone.0006693.g004
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conducted Kaplan Meier survival analyses in both the Hu et al.
and van de Vijver et al. data sets, which suggested that this profile
by itself may be of prognostic significance (Figure 6). The
classification of tumor samples into ‘‘high’’ vs. ‘‘low’’ expression
yielded starkly different survival curves in the Hu et al. data set,
while the differences in survival curves in the NKI295 sample set
were significant, yet decidedly more subtle. The reason for this
difference in the two data sets is likely due to the difference in
microarray platforms used in these studies. The Hu et al. study
utilized the identical microarray platform as this MYC study
permitting greater overlap of genes for subsequent survival
analysis. The NKI295 samples sets were analyzed on a different
microarray platform that provided a reduced set of overlapping
genes for the survival analysis.
Immunohistochemical analysis of MYC in breast tissues
To more thoroughly examine the relationship between tumor
subtype and MYC expression we performed immunohistochem-
Figure 5. The MYC gene expression signature in breast tumor tissue. A. The Core MYC signature gene list was extracted from a breast cancer
profiling dataset containing 105 tumor samples, 9 normal breast samples, and 26 sample pairs [37]. The data for these probes were hierarchically
clustered in two dimensions (genes and arrays). The order of breast tissue arrays (right) was preserved before linking to the Core MYC Signature data
(left). The merged data set was hierarchically clustered in one dimension (genes only) to give the presented format. B. The median centered c-MYC
RNA levels were extracted from the breast tissue expression profiling study. C. Pearson correlation between the Core MYC signature and the breast
cancer profiles.
doi:10.1371/journal.pone.0006693.g005
Table 4. Hu et al. samples clustered by the Core MYC Signature.
Left Right Total
Basal 46 0 46
HER2+/ER2 7 16 23
Luminal 2 60 62
NB 0 15 15
Total 55 91 146
Degrees of freedom: 3.
Chi Square = 117.
p-value,0.001.
The distribution of breast sample subtypes in the clusters presented in the
hierarchical clustering in Figure 5. Colored dendrogram branches from Figure 5
correspond to the colors used in this figure. LumA, Luminal type A. LumB,
Luminal type B. NB, normal breast.
doi:10.1371/journal.pone.0006693.t004
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istry for MYC protein expression in a subset of the tumors
presented in Livasy et al. [56]. This sample set represents a group
of breast tumors that were analyzed using RNA recovered from
fresh frozen material and for which paraffin-embedded materials
were also available for protein expression studies. We performed
IHC on 26 tumors in total, which included 11 Basal-like, 3
HER2+/ER2 and 12 Luminal/ER+ tumors using antibodies
against MYC. Representative IHC images of a basal-like tumor
and normal breast tissue are shown in Supplemental Figure S3.
Ten out of eleven of the basal-like tumors were positive for MYC,
as were two out of three HER2+/ER2. In contrast ten out of
twelve Luminal/ER+ tumors were negative for MYC. As was seen
in the gene expression studies, significant expression of MYC was
also seen in normal breast epithelial tissue (see Figure 5). These
protein expression results corroborate the gene expression results
for MYC itself and support the conclusion that the MYC gene
expression signature is a common, and perhaps critical, charac-
teristic of basal-like breast tumors.
Discussion
The fact that nearly all mammalian cell proliferation is
contingent on the expression of at least one MYC family protein
hints at the central role that MYC plays in normal growth. Given
its critical role in proliferation, it is not surprising that aberrant or
deregulated MYC expression participates in the malignant
transformation of normal cells into cancer cells. Numerous high-
throughput studies querying MYC regulated genes have been
published [22–29,57]. Perhaps surprisingly, little overlap in target
genes is found among all the studies. A trivial but important reason
for part of the non-overlap is that the genes on the microarrays
were different from study to study. As newer microarray platforms
and approaches have permitted complete or near complete
genome wide inquiry, this problem may be resolved. Numerous
other possible explanations stem from methodological differences
including choice of cell type, the levels of MYC overexpression,
time of overexpression, and the choice of MYC family member as
the exogenous transgene. We show here that the response to MYC
can vary significantly even in a single cell type (primary human
fibroblasts) depending on the timing and dosage of MYC delivery
(Supplemental Figure S2). The use of an estrogen receptor offers
the advantage of a rapid kinetic response, yet the artificial nature
of the fusion protein may alter the target gene response compared
to wt MYC. On the other hand, constitutive MYC expression may
induce a broad change in the transcriptional and posttranscrip-
tional program that includes many indirect effects. We sought to
overcome the limitations of each technique by focusing on genes
that responded to MYC induction in two independent protocols
within the same cell type. Both protocols show that MBII is critical
Table 5. Hu et al. sample subtypes sorted by low/high Core
MYC Signature average expression.
Left Right Total
Basal 14 32 46
LumA 28 13 41
LumB 13 8 21
HER2+/ER2 11 12 23
NB 7 8 15
Total 73 73 146
Degrees of freedom: 4.
Chi Square = 13.8.
p-value,0.01.
The distribution of Hu et al. breast sample subtypes in the low and high Core
MYC signature grouping. LumA, Luminal type A. LumB, Luminal type B. NB,
normal breast.
doi:10.1371/journal.pone.0006693.t005
Table 6. NKI295 sample subtypes sorted by low/high Core
MYC Signature average expression.
Left Right Total
Basal 9 44 53
LumA 80 43 123
LumB 32 23 55
HER2+/ER2 13 22 35
NB 13 16 29
Total 147 148 295
Degrees of freedom: 4.
Chi Square = 38.3.
p-value,0.001.
The distribution of NKI295 breast sample subtypes in the low and high Core
MYC signature grouping. LumA, Luminal type A. LumB, Luminal type B. NB,
normal breast.
doi:10.1371/journal.pone.0006693.t006
Figure 6. Kaplan Meier survival analyses in the Hu et al. and
NKI datasets. Patients from the Hu et al. (A) and the NKI295 (B)
datasets were grouped by low/high Core MYC signature average
expression. Survival analyses were performed on patients from these
groupings.
doi:10.1371/journal.pone.0006693.g006
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for the full induction and repression of the majority of MYC
responsive genes.
After defining a Core MYC signature, we compared the
transcriptional response in fibroblasts between MYCN overex-
pression and serum stimulation. This is of particular relevance
because MYC is an immediate early serum response gene, i.e.
induced by serum stimulation even in the absence of protein
synthesis. We anticipated that a significant fraction of the Core
MYC signature would be part of the serum response, perhaps
focused on a ‘delayed early’ gene set that is dependent on prior
MYC expression. Furthermore, previous studies have shown that
overexpression of MYC can bypass the need for serum growth
factors. We were surprised to find that only a fraction of the Core
MYC signature (10%) falls within the core serum response gene
set, which was also derived from primary human fibroblasts [20].
Furthermore, the response to MYC and serum is sometimes in
opposite directions for individual genes. Nevertheless, 23% of the
induced CSR genes are also MYC induced (Figure 4A). There are
at least three possible explanations for this observation (which are
not mutually exclusive). First, serum is a heterogeneous stimulus
that is likely to activate many different pathways. The final
expression levels of genes may be the consequence of the additive
or competing regulatory influences of different pathways. Hence,
while serum stimulation induces MYC expression, which may
alone lead to the activation of a gene, other serum activated
pathways may lead to a repressive regulatory influences on that
same gene. Second, deregulated MYC expression afforded by the
viral LTR and/or ER domain may exceed the level of MYC
protein induced by serum. MYC/Max binding to promoter sites is
dependent on expression level, with more sites occupied at higher
MYC levels [58]. However, it is not yet clear if elevated levels of
MYC lead to novel responsive genes or simply an exaggerated
response. Third, experimental differences in this study and the
CSR study may account for differences observed in the Myc
signature and the serum response. Some serum regulated genes
(which are also Myc regulated) may have achieved their maximum
response before Myc was overexpressed in our system since cells
were not serum starved before MYCN-ER activation. However,
the bulk of the Myc signature genes (genes whose transcripts do
change with MYCN overexpression in the presence of serum) do
not have the cognate response to serum (Figure 4B). It is clear that
the cellular response to MYC alone is qualitatively distinct from a
serum response, with a wide range of genes activated and
repressed that are normally unaffected by serum growth factors.
A previous study reached a similar conclusion that MYC induction
and serum stimulation were distinct using a B cell model [59].
While many studies have focused on the discovery of MYC
target genes, few have examined the genome-wide transcriptional
changes induced by MYC. A recent study of gene expression in a
murine model of prostatic intraepithelial neoplasia (mPIN) created
by targeting MYC overexpression to the prostate has defined a
prostate cancer specific MYC induced gene expression signature
[60]. In another study, analysis of gene expression profiles of
neuroblastomas identified coordination between high MYCN
levels and high levels of another oncogene, H-Twist, that functions
to antagonize MYCN’s proapoptotic effects [61]. Recently, Adler
et al. show that the underlying drivers of the wound signature in
human breast cancer were the amplification of MYC and CSN5
[21]. The wound signature is most robustly recapitulated by the
overexpression of both MYC and CSN5. In most of these studies,
comparison between normal tissues with low MYC levels to tumor
tissues with high MYC levels was used to define the MYC
dependent gene expression profile. Because the comparisons are to
tumors with high MYC expression that are likely to have suffered
multiple other genetic lesions, these strategies reveal the
transcriptional profile after all genetic lesions have occurred, not
just those associated with MYC activation alone. Since the Core
MYC signature defined in the present study includes both kinetic
data and an enrichment for MYC/Max binding sites, it is more
likely to contain direct MYC targets. A fundamental MYC gene
expression profile may be broadly relevant to different types of
MYC-driven tumors and should facilitate elucidation of the
complex cellular responses that mediate the biological activities of
the MYC protein.
A key finding of this study is the distinct correlation between the
Core MYC signature and tumors of the basal-like subtype of
breast cancer. Our IHC data corroborate the association between
high MYC expression and the basal-like tumor subtype, and this
strongly suggests a common underlying biological program in
effect in both the basal-like tumors and the MYC induced
fibroblast cells. From these data it is not formally possible to
conclude that expression of the Core MYC signature orchestrates
the typically aggressive behavior of the basal-like breast tumors;
however, it is likely that this expression profile is not inconse-
quential. In support of this direct link is the finding that MYC
mRNA expression and the Core MYC signature are linked to
basal-like tumors in two different patient data sets, and in both
bases, the Core MYC signature is also of prognostic value. Further
support for a link between MYC and basal-like breast cancers
comes from studies of the transformation of human mammary
epithelial cells (which are basal-like cell lines [62,63]) with
hTERT, SV40 T-antigen and H-Ras. Transformation was
frequently accompanied with the amplification of MYC, suggest-
ing that even in the presence of multiple other oncogenes,
amplification of MYC is still required to transform this basal-like
cell type [64]. Furthermore, high levels of MYC can partially
transform immortalized human mammary epithelial cells [65]. A
recent meta-analysis study further supports elevated MYC and
E2F activity in the basal-subtype tumors [66]. Lastly, it has also
been shown that MYC is amplified in many BRCA1-associated
tumors [67], which are known to be mostly basal-like tumors [68].
Thus, basal-like mammary epithelial cells are exquisitely sensitive
to MYC overexpression, and it is likely that MYC is a significant
etiological factor in the development of this subtype of breast
tumor.
In conclusion, using two different cell culture models of aberrant
MYCN expression, we have defined a fundamental gene
expression profile that is less subject to many of the common
experimental variables. The Core MYC Signature is distinct from
the Core Serum Response, yet the two profiles share statistically
significant gene expression responses. The Core MYC Signature
has clinical relevance as this profile is identified in the basal-like
subtype of breast cancer expression profiles, which typically harbor
the highest levels of MYC expression among the different breast
cancer subtypes. Importantly, the Core MYC signature can be
used to deduce an underlying genetic program that is likely to
powerfully contribute to a clinical phenotype. Therefore, the
presence of the Core MYC Signature may predict clinical
responsiveness to drugs that are designed to disrupt MYC-
mediated phenotypes.
Supporting Information
Figure S1 Analysis of expression from transgenes Whole cell
lysates of primary human fibroblast cells infected with pLPCX
(lane 1) pLPC-MYCN-ER (lane 2), and pLPC-MYCN(del-MBII)-
ER (lane 3) were resolved by PAGE and transferred to PVDF for
western blot analysis. Because exogenous proteins were FLAG-
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tagged, western analysis was performed using antibodies specific to
the FLAG epitope.
Found at: doi:10.1371/journal.pone.0006693.s001 (0.19 MB TIF)
Figure S2 MYC responsive probes in one, but not both
experimental designs. Data from the time course and steady state
experiments for the non-overlapping regions of the Venn diagram
are displayed in Java Treeview format. Region A refers to probes
that were called MYC-ER responsive, but not MYC responsive.
Region B refers to probes that were called MYC responsive, but
not MYC-ER responsive.
Found at: doi:10.1371/journal.pone.0006693.s002 (0.46 MB TIF)
Figure S3 c-MYC protein in normal and basal breast carcinoma
tissue Paraffin sections of normal breast tissue (A) and basal breast
carcinoma tissue (B) were stained with a c-MYC antibody.
Found at: doi:10.1371/journal.pone.0006693.s003 (4.32 MB TIF)
Table S1 Unigene IDs of genes identified as responsive to
MYCNER and steady state MYCN.
Found at: doi:10.1371/journal.pone.0006693.s004 (0.50 MB
XLS)
Table S2 GO term enrichment analyses.
Found at: doi:10.1371/journal.pone.0006693.s005 (1.61 MB
XLS)
Table S3 Comparison on MYC responsive gene identified in
this study to the MYC target gene database.
Found at: doi:10.1371/journal.pone.0006693.s006 (0.26 MB
XLS)
Table S4 Comparison of genes identified in this study and in the
Core Serum Response study.
Found at: doi:10.1371/journal.pone.0006693.s007 (5.41 MB
XLS)
Table S5 Comparison of this study with other studies identifying
direct MYC targets.
Found at: doi:10.1371/journal.pone.0006693.s008 (0.45 MB
XLS)
Table S6 Direction of MYC signature genes that have evidence
for MYC binding.
Found at: doi:10.1371/journal.pone.0006693.s009 (0.09 MB
XLS)
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